GW Pharmaceuticals plc to Report Financial Results and Operational Progress for the Third Quarter Ending September 30, 2019 a...
October 09 2019 - 7:00AM
GW Pharmaceuticals plc (Nasdaq: GWPH, “GW” or “the Company”), a
biopharmaceutical company focused on discovering, developing and
commercializing novel therapeutics from its proprietary cannabinoid
product platform, will announce on November 5th, 2019 its financial
results for the third quarter ending September 30th, 2019. GW will
also host a conference call the same day at 4:30 p.m. ET.
Conference call information will be provided in the financial
results press release. A replay of the call will also be available
through the Company's website (www.gwpharm.com) shortly after the
call.
About GW Pharmaceuticals plc and
Greenwich Biosciences, Inc.
Founded in 1998, GW is a biopharmaceutical
company focused on discovering, developing and commercializing
novel therapeutics from its proprietary cannabinoid product
platform in a broad range of disease areas. GW’s lead product,
EPIDIOLEX (cannabidiol) oral solution is commercialized in the US
by its U.S. subsidiary Greenwich Biosciences for the treatment of
seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet
syndrome in patients two years of age or older. This product has
received approval in Europe under the tradename EPIDYOLEX. The
Company continues to evaluate EPIDIOLEX in additional rare
conditions including Tuberous Sclerosis Complex (TSC) and Rett
syndrome. GW commercialized the world’s first plant-derived
cannabinoid prescription drug, Sativex® (nabiximols), which is
approved for the treatment of spasticity due to multiple sclerosis
in numerous countries outside the United States and for which the
Company is now advancing a late stage program in order to seek FDA
approval. The Company has a deep pipeline of additional cannabinoid
product candidates which includes compounds in Phase 1 and 2 trials
for epilepsy, autism, glioblastoma, and schizophrenia. For further
information, please visit www.gwpharm.com.
Enquiries:
GW Pharmaceuticals plc |
|
Stephen Schultz, VP Investor Relations (U.S.) |
917 280 2424 / 401 500 6570 |
GW Pharmaceuticals (NASDAQ:GWPH)
Historical Stock Chart
From Mar 2024 to Apr 2024
GW Pharmaceuticals (NASDAQ:GWPH)
Historical Stock Chart
From Apr 2023 to Apr 2024